8-K: Quantum-Si Reports First Quarter Revenue Exceeding $1 Million, Secures $86 Million in Capital

Quantum-Si announces its Q4 and full-year 2024 financial results, highlighted by first quarterly revenue over $1 million and $86 million in capital raises.

Summary

• Quantum-Si Incorporated reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company achieved its first quarterly revenue exceeding $1 million in Q4 2024.
• Full-year 2024 revenue reached $3.1 million, representing a 183% year-over-year growth.
• Quantum-Si raised over $86 million between Q4 2024 and the first week of 2025, extending its cash runway into the second half of 2027.
• The company launched Platinum Pro in January 2025, with shipping expected to begin in Q1 2025.
• Quantum-Si also launched the v2 Library Preparation Kit and a new Barcoding Kit in December 2024.
• The new v4 Sequencing Kit is on track to launch in Q3 2025.
• The company's Q4 2024 revenue was $1.2 million, with a gross profit of $0.6 million and a gross margin of 51%.
• For the full year 2024, gross profit was $1.6 million, and gross margin was 52%.
• Total operating expenses for Q4 2024 were $31.3 million, while adjusted total operating expenses were $26.7 million.
• The net loss for Q4 2024 was $33.1 million, and the adjusted EBITDA was negative $25.1 million.
• As of December 31, 2024, Quantum-Si's cash and cash equivalents and investments in marketable securities were $209.6 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong revenue growth, successful capital raise, and product launches. However, the significant net losses and ongoing operating expenses temper the overall outlook.

Positives

• Quantum-Si achieved its first quarter with revenue exceeding $1 million in Q4 2024.
• The company's full-year 2024 revenue grew by 183% year-over-year, reaching $3.1 million.
• The company raised over $86 million in capital between Q4 2024 and the first week of 2025.
• The capital raise extends the company's cash runway into the second half of 2027.
• The company launched Platinum Pro in January 2025, with shipping expected to commence in Q1 2025.
• Gross margin for the full year 2024 was 52%.

Negatives

• The company reported a net loss of $33.1 million in Q4 2024, compared to a net loss of $22.0 million in the same period of the prior year.
• The adjusted EBITDA was negative $25.1 million in Q4 2024.
• Total operating expenses were $31.3 million in Q4 2024.

Risks

• The company's periodic gross margin rate is expected to be variable in the near term due to the initial stages of commercialization and the timing and mix of product sales.
• The company's future performance and development and commercialization of products and services are subject to significant risks and uncertainties.
• The company's ability to raise financing in the future is uncertain.

Future Outlook

Quantum-Si anticipates significant revenue growth in 2025, driven by the launch of Platinum Pro, the Avantor distribution relationship, and the international distribution partner network. The company also expects a strong pipeline of scientific data releases and the launch of version 4 of its Sequencing Kit.

Management Comments

• Jeff Hawkins, President and CEO, stated he was very pleased with how the company closed out 2024, delivering the first quarter in excess of $1 million in revenue.
• Hawkins noted the successful investor and analyst day where the company showcased its technology roadmap and announced its next-generation Proteus development program.
• Hawkins mentioned the company was able to raise over $86 million in capital in a generally challenging macro market, which demonstrates the overall confidence in Quantum-Si and its strategic roadmap.
• Hawkins stated that the company expects to achieve even greater results in 2025.

Industry Context

Quantum-Si operates in the proteomics market, which is experiencing growth due to advancements in protein sequencing technologies. The company's focus on Next-Generation Protein Sequencing positions it to compete with existing proteomic tools and contribute to advancements in research, drug discovery, and diagnostics.

Comparison to Industry Standards

• It is difficult to compare Quantum-Si directly to industry standards without specific competitor data, but companies like Pacific Biosciences and Illumina in the DNA sequencing space have achieved significant revenue growth and market capitalization.
• Quantum-Si's 183% year-over-year revenue growth suggests strong market traction, but its net losses indicate that it is still in a growth phase and investing heavily in R&D and commercialization.
• The $86 million capital raise provides a substantial runway for the company to execute its strategic plan.

Stakeholder Impact

• Shareholders: The results show strong revenue growth and a solid cash position, which is generally positive.
• Employees: The restructuring program may have impacted some employees, but the company's focus on commercialization and new product development could create new opportunities.
• Customers: The launch of new products like Platinum Pro and the v2 Library Preparation Kit should provide customers with improved tools for proteomic research.
• Suppliers: Increased sales and production could lead to increased demand for supplies and services.
• Creditors: The company's strong cash position reduces the risk for creditors.

Next Steps

• Commence shipping of Platinum Pro in Q1 2025.
• Bring the Avantor North American commercial distribution relationship online during Q1.
• Launch the new v4 Sequencing Kit in Q3 2025.
• Release scientific data throughout the year.

Key Dates

Keywords

Quantum-Si, Financial Results, Protein Sequencing, Revenue, Capital Raise, Platinum Pro, Proteomics